Gemcitabine anticancer activity enhancement by water soluble celecoxib/sulfobutyl ether-β-cyclodextrin inclusion complex

被引:40
作者
Rescifina, Antonio [1 ]
Surdo, Emanuela [2 ]
Cardile, Venera [3 ]
Avola, Rosanna [3 ]
Graziano, Adriana Carol Eleonora [3 ]
Stancanelli, Rosanna [2 ]
Tommasini, Silvana [2 ]
Pistara, Venerando [1 ]
Ventura, Cinzia Anna [2 ]
机构
[1] Univ Catania, Dept Drug Sci, Vle A Doria 6, I-95125 Catania, Italy
[2] Univ Messina, Dept Chem Biol Pharmaceut & Environm Sci, Vle F Stagno Dalcontres 31, I-98166 Messina, Italy
[3] Univ Catania, Dept Biomed & Biotechnol Sci, Via Santa Sofia 97, I-95125 Catania, Italy
关键词
Celecoxib; Sulfobutyl-ether-beta-cyclodextrin; Gemcitabine; NMR spectroscopy; Computational studies; In vitro biological studies; CELL LUNG-CANCER; IN-VITRO; PHASE-II; PHYSICOCHEMICAL CHARACTERIZATION; ANTIINFLAMMATORY ACTIVITY; EQUILIBRIUM-CONSTANTS; DOWN-REGULATION; FORCE-FIELDS; CELECOXIB; DOCETAXEL;
D O I
10.1016/j.carbpol.2018.11.060
中图分类号
O69 [应用化学];
学科分类号
081704 ;
摘要
We investigated the complexation of celecoxib (CCB) into sulfobuthyl-ether-beta-cyclodextrin (SBE-beta 1-CD) for the realization of an inhalable dry-powder formulation containing gemcitabine (GEM) for lung anticancer therapy. Complexation increased the water solubility of CCB (0.003 mg/mL and 0.834 mg/mL for CCB free and complexed, respectively) and produced a quantitative dissolution of the drug within 15 min. The CCB/SBE-beta-CD inclusion complex showed a high stability constant (8131 M-1) not influenced by the presence of GEM in solution. Two-dimensional NMR experiments and computational studies demonstrated that the pyrazole ring of CCB penetrates deeper into SBE-beta-CD from the secondary rim. The aromatic rings are positioned at the edge of the cavity, establishing hydrogen bonds with the SBE-beta-CD that stabilized the complex. CCB showed limited cytotoxic activity on A549 cell lines. Complexation significantly increased activity passing from 30% to 45% cell mortality. Moreover, CCB/SBE-beta-CD strongly improved the cytotoxicity of GEM, observing about 60% of cell mortality for the combined formulation.
引用
收藏
页码:792 / 800
页数:9
相关论文
共 67 条
[31]   New Ways to Boost Molecular Dynamics Simulations [J].
Krieger, Elmar ;
Vriend, Gert .
JOURNAL OF COMPUTATIONAL CHEMISTRY, 2015, 36 (13) :996-1007
[32]   YASARA View-molecular graphics for all devices-from smartphones to workstations [J].
Krieger, Elmar ;
Vriend, Gert .
BIOINFORMATICS, 2014, 30 (20) :2981-2982
[33]   Celecoxib suppresses fibroblast growth factor-2 expression in pancreatic ductal adenocarcinoma PANC-1 cells [J].
Li, Jing ;
Luo, Miaosha ;
Wang, Yan ;
Shang, Boxin ;
Dong, Lei .
ONCOLOGY REPORTS, 2016, 36 (03) :1345-1352
[34]   INTRAMOLECULAR VANDERWAALS INTERACTIONS AND CHEMICAL-SHIFTS - A MODEL FOR BETA-EFFECTS AND GAMMA-EFFECTS [J].
LI, S ;
CHESNUT, DB .
MAGNETIC RESONANCE IN CHEMISTRY, 1985, 23 (08) :625-638
[35]   Cellular FLICE-inhibitory protein down-regulation contributes to celecoxib-induced apoptosis in human lung cancer cells [J].
Liu, Xiangguo ;
Yue, Ping ;
Schonthal, Axel H. ;
Khuri, Fadlo R. ;
Sun, Shi-Yong .
CANCER RESEARCH, 2006, 66 (23) :11115-11119
[36]  
Loftsson Thorsteinn, 2005, Expert Opin Drug Deliv, V2, P335, DOI 10.1517/17425247.2.1.335
[37]   Pharmaceutical applications of cyclodextrins: basic science and product development [J].
Loftsson, Thorsteinn ;
Brewster, Marcus E. .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 2010, 62 (11) :1607-1621
[38]  
Masferrer JL, 2000, CANCER RES, V60, P1306
[39]   Celecoxib-cyclodextrin systems: Characterization and evaluation of in vitro and in vivo advantage [J].
Nagarsenker, MS ;
Joshi, MS .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2005, 31 (02) :169-178
[40]   Docetaxel and cyclooxygenase-2 inhibition with celecoxib for advanced non-small cell lung cancer progressing after platinum-based chemotherapy: a multicenter phase II trial [J].
Nugent, FW ;
Mertens, WC ;
Graziano, S ;
Levitan, N ;
Collea, R ;
Gajra, A ;
Marshall, J ;
McCann, J .
LUNG CANCER, 2005, 48 (02) :267-273